JAZZ

JAZZ

Jazz Pharmaceuticals is a biopharmaceutical company focused on developing treatments for sleep disorders and oncology.
It has established a strong identity as a specialty drugmaker, known for its expertise in neuroscience and its portfolio of medicines addressing high-need patient populations.

$170.81 +8.38 (+5.16%)

Updated: January 14, 2026, 16:00 EST

Analyzed by Rockflow Bobby Quantitative Model āœ“ Updated Daily

Investment Opinion: Should I buy JAZZ Today?

Analysis of JAZZ Stock

Technical Perspective JAZZ shows strong momentum with a significant 17.58% rally over three months, substantially outperforming the market. However, trading near the top of its 52-week range suggests it may be approaching overbought conditions. The recent slight pullback could indicate a healthy consolidation, but new investors should be cautious about entry timing.

Fundamental Assessment The company demonstrates solid revenue growth but faces profitability challenges, with recent net margins boosted by non-operating factors. While liquidity is adequate, high leverage and weak cash flow relative to debt obligations present concerns. Operational efficiency is mixed, with strong fixed asset utilization offset by poor working capital management.

Valuation & Risk Considerations JAZZ appears richly valued on sales and cash flow metrics, though its forward P/E suggests market optimism about future profitability. The stock's low beta provides defensive characteristics, but its substantial maximum drawdown indicates potential for sharp declines during market stress.

Investment Recommendation

Based on comprehensive analysis, JAZZ presents a cautious case. While revenue growth and anticipated profitability are positive, elevated valuation, financial leverage, and recent price appreciation limit upside potential. Investors might consider waiting for a better entry point or more consistent operational improvement. The stock appears more suitable for risk-tolerant investors comfortable with its volatility profile.

*Note: This is not investment advice, for reference only.*

CTA Banner

JAZZ 12-Month Price Forecast

RockFlow Model Forecast: Three Scenarios for 2026

Based on comprehensive analysis, JAZZ's 12-month outlook is nuanced. Key catalysts include continued revenue growth and market optimism for improved profitability reflected in its forward P/E. However, significant risks persist from its rich valuation, high financial leverage, and potential for a sharp correction given its substantial maximum drawdown and recent strong price appreciation. With no analyst target price available, the stock's path is highly dependent on demonstrating sustained operational improvement; investors should wait for a clearer inflection point in cash flow generation or a more attractive entry point before establishing a position.

Wall Street Consensus

Most Wall Street analysts are optimistic about JAZZ's 12-month outlook, with consensus target around $170.81, indicating expected upside potential.

Average Target
$170.81
17 analysts
Implied Upside
+0%
vs. current price
Analyst Count
17
covering this stock
Price Range
$137 - $222
Analyst target range
Buy Buy
15 (88%)
Hold Hold
2 (12%)
Sell Sell
0 (0%)

Bulls vs Bears: JAZZ Investment Factors

Overall, JAZZ has investment potential but also faces challenges. Here are key factors to weigh before investing.

Bullish Bullish
  • Positive gastric cancer drug results: Strong clinical data for ZaiLab partnership driving significant stock gains
  • Board expansion with industry veteran: Appointment of Ted W. Love adds pharmaceutical expertise to leadership
  • Analyst price target increases: Truist Securities raised target to $230, maintaining Buy rating
  • Strong quarterly performance: Third quarter 2025 results showing improved financial metrics
  • Recent stock momentum: Shares up 25% with positive investor sentiment building
Bearish Bearish
  • Valuation concerns after rally: Stock cooled down after rapid gains, raising valuation questions
  • Revenue sustainability required: Need improved revenues to justify current price levels
  • Competitive pharmaceutical landscape: Operating in highly competitive cancer treatment market
  • Pipeline dependency risk: Heavy reliance on successful clinical trial outcomes
Reward Banner

JAZZ Technical Analysis

JAZZ has demonstrated mixed performance with notable strengths highlighted by its significant 3-month rally and current position trading near the upper end of its 52-week range. The stock's recent momentum has substantially outperformed the broader market over this period.

Short-term performance reveals a dichotomy between a slight 1-month pullback and a strong 3-month advance of 17.58%. This 3-month performance significantly outpaces the general market by 14.21%, indicating strong relative strength and positive momentum, despite the minor recent dip suggesting a potential consolidation phase.

Currently trading at $162.43, JAZZ is positioned in the upper quartile of its 52-week range ($95.49 - $182.99), approximately 73% above its low. While not at an extreme peak, this elevated level, combined with the recent rally, suggests the stock may be approaching overbought territory rather than being oversold, warranting caution for new entries.

šŸ“Š Beta
0.27
0.27x market volatility
šŸ“‰ Max Drawdown
-32.2%
Largest decline past year
šŸ“ˆ 52-Week Range
$95-$183
Price range past year
šŸ’¹ Annual Return
+38.6%
Cumulative gain past year
Period JAZZ Return S&P 500
1m +2.0% +1.3%
3m +26.1% +5.7%
6m +53.1% +10.6%
1y +38.6% +16.5%
ytd -1.4% +1.1%

JAZZ Fundamental Analysis

Revenue & Profitability: JAZZ shows significant revenue growth from Q2 to Q3 2025, increasing from $1.05 billion to $1.13 billion. However, profitability metrics exhibit volatility with operating margins improving from negative territory to 5.1%, while net profit margin reached 22.3% in Q3 primarily due to unusual tax benefits rather than operating performance.

Financial Health: The company maintains adequate liquidity with current and quick ratios of 1.65 and 1.44 respectively, but carries substantial leverage with a debt-to-equity ratio of 1.37. The interest coverage ratio of 1.18 indicates minimal buffer for debt servicing, while weak cash flow to debt ratio of 0.09 suggests limited cash generation relative to obligations.

Operational Efficiency: JAZZ demonstrates mixed operational metrics with a reasonable ROE of 6.4% but concerningly low asset turnover of 0.10, indicating inefficient asset utilization. The extended cash conversion cycle of 177 days reflects poor working capital management, though fixed asset turnover of 4.5 suggests reasonable utilization of property and equipment.

Quarterly Revenue
$1.1B
2025-09
Revenue YoY Growth
+6.7%
YoY Comparison
Gross Margin
N/A%
Latest Quarter
Free Cash Flow
$0.1B
Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

RockFlow Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

Try Now & Get Tesla Stock Reward

Valuation Analysis: Is JAZZ Overvalued?

Valuation Level: The negative TTM P/E ratio indicates Jazz is currently unprofitable on a trailing basis, making that metric uninformative. However, a forward P/E of approximately 8.0 suggests the market anticipates a significant return to profitability. Notably elevated EV/EBITDA and PS ratios relative to typical value thresholds suggest the stock may be richly valued based on current sales and cash flow, despite the attractive forward earnings multiple.

Peer Comparison: A conclusive valuation assessment is challenging without specific industry average data for comparison. The absence of industry benchmarks prevents definitive interpretation of the PS ratio of 2.39, PB ratio of 2.51, and the exceptionally high EV/EBITDA of 51.7. A meaningful conclusion on relative valuation would require this contextual industry data.

Current PE
-27.7x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range -127Ɨ-1462Ɨ
vs. Industry Avg
N/A
Industry PE ~N/AƗ
EV/EBITDA
51.7x
Enterprise Value Multiple

Investment Risk Disclosure

Volatility Risk

JAZZ exhibits significantly low Beta of 0.274, indicating it is about 73% less volatile than the broader market, which provides defensive characteristics. However, the -32.18% maximum drawdown over the past year highlights substantial downside volatility and price erosion during market stress, suggesting investors should be prepared for significant interim losses despite the stock's low correlation to market movements.

Other Risks

The absence of reported short interest eliminates concerns about bearish speculative pressure or potential short squeezes, but this may also reflect low trading interest or analyst coverage. Liquidity risk should be assessed separately, as low trading volumes could exacerbate volatility and challenge entry/exit at desired prices, particularly given the stock's demonstrated susceptibility to sharp declines.

FAQs

Is JAZZ a good stock to buy?

Neutral to slightly bearish. While JAZZ has strong recent momentum and positive analyst sentiment, its elevated valuation after a significant rally and weak financial health metrics (high debt, low interest coverage) are concerning. This stock is best suited for speculative investors comfortable with high risk, given its dependence on pipeline success and competitive market pressures.

Is JAZZ stock overvalued or undervalued?

Based on the provided data, JAZZ stock appears to be overvalued. While the forward P/E of ~8 seems attractive, this is overshadowed by an extremely high EV/EBITDA of 51.7 and a PS ratio of 2.39, which are typically considered lofty and suggest the market prices in significant future growth. The primary reasons for this premium valuation are the anticipated return to profitability, as indicated by the forward P/E. However, this optimism is counterbalanced by weak fundamentals, including high leverage with a concerning interest coverage ratio (1.18), poor asset turnover (0.10), and profitability that was recently boosted by non-operating factors. The elevated multiples are not justified by the current operational efficiency and financial health.

What are the main risks of holding JAZZ?

Based on the provided information, here are the key risks of holding JAZZ stock, ordered by importance:

1. Financial Risk: The company's high debt load and weak interest coverage ratio of 1.18 create significant vulnerability to earnings downturns or rising interest rates, jeopardizing its ability to service its obligations. 2. Business/Operational Risk: Extremely inefficient operations, highlighted by a low asset turnover of 0.10 and an excessively long cash conversion cycle of 177 days, pose a fundamental threat to sustainable profitability and cash flow generation. 3. Volatility/Pricing Risk: Despite a low beta, the stock has experienced a substantial -32.18% maximum drawdown, indicating high downside volatility that could lead to significant interim losses, a risk heightened by its current position near the top of its 52-week range following a strong rally.

What is the price forecast for JAZZ in 2026?

Based on current analysis, JAZZ's 2026 forecast is highly speculative given the lack of analyst consensus and the company's mixed fundamentals. A base case target could range from $140-$160, reflecting persistent leverage and execution risks, while a bull case of $180+ would require successful debt reduction and improved operational efficiency. Key growth drivers are dependent on stabilizing core profitability beyond one-time benefits and demonstrating sustained revenue growth from its product portfolio. The main assumptions include no major pipeline setbacks and the company's ability to manage its significant financial leverage. This forecast carries high uncertainty due to JAZZ's volatile earnings, weak cash flow generation, and the absence of clear analyst guidance.